New single-isomer compounds on the horizon

CNS Spectrums

Volumn 7, Issue 4 SUPPL. 1, 2002, Pages 45-54

  Gal, Joseph ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 [3,5 BIS(TRIFLUOROMETHYL)PHENYL]ETHOXY] 3 (4 FLUOROPHENYL) 4 (3 OXO 1 PHOSPHORYL 1,2,4 TRIAZOL 5 YLMETHYL)MORPHOLINE; ABARELIX; AMFEBUTAMONE; AMLODIPINE; APREPITANT; CISAPRIDE; DOXAZOSIN; ESCITALOPRAM; FLUOXETINE; FORMOTEROL; ITRACONAZOLE; LANSOPRAZOLE; LEVOCETIRIZINE; LOMEFLOXACIN; METHYLPHENIDATE; ONDANSETRON; OXYBUTYNIN; PANTOPRAZOLE; POSACONAZOLE; PREGABALIN; ROSUVASTATIN; SIBUTRAMINE; SITAFLOXACIN; ZOPICLONE;

CHIRALITY; CONFERENCE PAPER; DEPRESSION; DRUG INDICATION; DRUG SAFETY; DRUG STRUCTURE; ENANTIOMER; FOOD AND DRUG ADMINISTRATION; ISOMERISM; PRACTICE GUIDELINE; PRIORITY JOURNAL; RACEMIC MIXTURE; STEREOISOMERISM; STRUCTURE ANALYSIS; URINE INCONTINENCE;

EID: 0036087570     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1092852900028601     Document Type: Conference Paper

References (46)

1. Medicinals of plant origin: Historical aspects
2. Opioid analgesics and antagonists
3. Bias in pharmacokinetics and clinical pharmacology
4. Stereochemical aspects of drug action and disposition
5. FDA's policy for the development of new stereoisomeric drugs
6. Chiral drugs
7. Chiral switches
8. Sepracor: Skating on thin 'ice'
9. Counting on chiral drugs
10. Hypersensitivity immune-reaction as a mechanism for dilevalol-associated hepatitis
11. D-Sotalol: Death by the SWORD or deserving further consideration for clinical use?
12. Eli Lilly pulls the plug on Prozac isomer drug
13. Congestive heart failure and ventricular arrhythmias. Problems of treatment
14. Differences in the effects of urinary incontinence agents S-oxybutynin and terodiline on cardiac K+ currents and action potentials
15. Comparison of the antimuscarinic and antispasmodic actions of racemic oxybutynin and desethyloxybutynin and their enantiomers with those of racemic terodiline
16. The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer
17. Escitalopram metabolism in vitro
18. Effects of cotinine on cigarette self-administration
19. Nornicotine pretreatment decreases intravenous nicotine self-administration in rats
20. Contraindicated use of cisapride-impact of food and drug-administration regulatory action
21. Enantioselective behavioral effects of sibutramine metabolites
22. ZD4522 (rosuvastatin) compared with diet and maximal lipid therapy in patients with heterozygous familial hypercholesterolemia
23. ZD4522 is superior to pravastatin and simvastatin in reducing low density lipoprotein cholesterol, enabling more hypercholesterolemic patients to achieve target low density lipoprotein cholesterol guidelines
24. ZD4522 is superior to atorvastatin in decreasing low density lipoprotein cholesterol and increasing high density lipoprotein cholesterol in patients with type IIa or IIb hypercholesterolemia
25. ZD4522 is superior to atorvastatin in the treatment of patients with heterozygous familial hypercholesterolemia
26. Reduction of LDL-cholesterol and elevation of HDL-cholesterol in subjects with primary hypercholesterolemia by SCH58235: Pooled analysis of the two phase II studies
27. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461
28. In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts
29. Interactions of posaconazole and flucytosine against Cryptococcus neoformans
30. Update on drug interactions with azole antifungal agents
31. Sitafloxacin (DU-6859a) and trovafloxacin: Postantibiotic effect and in vitro interactions with rifampin on methicillin-resistant Staphylococcus aureus
32. Mechanism of action of 1-(-D-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-(-D-dioxolane guanosine
33. Pharmacokinetics of (-)-(-D-dioxolane guanine and prodrug (-)-(-D-2,6-diaminopurine dioxolane in rats and monkeys
34. The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water-soluble phosphoryl prodrug, L759,298, inhibit acute and delayed cisplatin-induced emesis in ferrets
35. Discovery of the anti-depressant and anti-emetic efficay of substance P receptor (NK1) antagonists
36. Novel strategies for pharmacotherapy of depression
37. The substance P antagonist L-754,030 (MK-0869) is ineffective in the treatment of postherpetic neuralgia
38. Substance P receptor antagonist I: Conversion of phosphoramidate prodrug after i.v. administration to rats and dogs
39. 3-Substituted GABA analogs with central nervous system activity: A review
40. Progress report on new antiepileptic drugs: A summary of the fourth Eilat conference (EILAT IV)
41. Benzodiazepines and anticonvulsants for social phobia (social anxiety disorder)
42. Peptides: Boom in the making
43. Technology evaluation: Abarelix, Praecis pharmaceuticals